Reduction of fibrosis in a rat model of non-alcoholic steatohepatitis cirrhosis by human HGF gene transfection using electroporation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 8 PART2, 2008, Pages

  Kiyama, Shigeru ^a   Yamada, Takuya ^a   Iwata, Hisashi ^a   Sekino, Takafumi ^a   Matsuo, Hiroshi ^a   Yoshida, Naomasa ^a   Miyahara, Toshiyuki ^a   Umeda, Yukio ^a   Matsuno, Yukihiro ^a   Kimura, Masaki ^a   Matsumoto, Kunio ^b   Nakamura, Toshikazu ^b   Takemura, Hirofumi ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Electroporation; Gene therapy; Liver cirrhosis; Non alcoholic steatohepatitis

Indexed keywords

8 AZAGUANINE; CHOLINE; GREEN FLUORESCENT PROTEIN; OIL SCARLET; PLASMID DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCULATION; CONTROLLED STUDY; DIET; ELECTROPORATION; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; GENE; GENETIC TRANSFECTION; HEPATOCYTE GROWTH FACTOR GENE; HISTOPATHOLOGY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; STAINING; WISTAR RAT;

EID: 48549106867     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05111.x     Document Type: Article

References (37)

1. Komeda T. Obesity and NASH in Japan. Hepatol. Res. 2005 33 : 83 6.
2. Ludwig J, Viggiano TR, McGill DB et al. Nonalcoholic steatohepatitis. Mayo Clin. Proc. 1980 55 : 434 8.
3. Matteoni CA, Younossi ZM, Granlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999 116 : 1413 19.
4. Lieber C, Leo M, Mak K et al. Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem. Biophys. Res. Commun. 2004 315 : 699 703.
5. Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc. Natl. Acad. Sci. USA 1986 83 : 6489 93.
6. Kosai K, Matsumoto K, Funakoshi H et al. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology 1999 30 : 151 9.
7. Liu Y. Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanism. Am. J. Physiol. 1999 227 : F624 F633.
8. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997 276 : 60 6.
9. Okano J, Shiota G, Kawasaki H. Protective action of hepatocyte growth factor for acute liver injury caused by d-galactosamine in transgenic mice. Hepatology 1997 26 : 1241 9.
10. Xue F, Takahara T, Yata Y et al. Attenuated acute liver injury in mice by naked hepatocyte growth factor gene transfer into skeletal muscle with electroporation. Gut 2002 50 : 558 62.
11. Matsuno Y, Iwata H, Umeda Y et al. Hepatocyte growth factor gene transfer into the liver via the portal vein using electroporation attenuates rat liver cirrhosis. Gene Ther. 2003 10 : 1559 66.
12. Best H, Hartroft S, Lucas C et al. Liver damage produced by feeding alcohol or sugar and its prevention by choline. BMJ 1947 2 : 1001 6.
13. Shibayama Y. Localization of vascular resistance and significance of hepatic artery playing for development of portal hypertension in the choline deficient diet induced rat liver cirrhosis. Kanzou 1975 16 : 332 40.
14. Nakano M. Morphogenesis of septa in hepatic fibrosis induced by choline deficiency in rats. Correlation between Ito cells, pericellular fibrosis, and septa. Acta Pathol. Jpn. 1986 36 : 1643 52.
15. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high expression transfectants with a novel eukaryotic vector. Gene 1991 108 : 193 9.
16. Zhang G, Gurtu V, Kain SR. An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells. Biochem. Biophys. Res. Commun. 1996 227 : 701 11.
17. Okabe M, Ikawa M, Kominami K et al. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 1997 407 : 313 19.
18. Seki T, Hagiya M, Shimonishi M et al. Organization of human hepatocyte growth factor encoding gene. Gene 1991 102 : 213 19.
19. Suzuki T, Shin BC, Fujikura K et al. Direct gene transfer into rat liver cells by in vivo electroporation. FEBS Lett. 1998 425 : 436 40.
20. Yamada A, Matsumoto K, Iwanari H et al. Rapid and sensitive enzyme-linked immunosorbent assay for measurement of HGF in rat and human tissues. Biomed. Res. 1995 16 : 105 14.
21. Sakaida I, Kubota M, Kayano K et al. Prevention of fibrosis reduces enzyme-altered lesions in the rat. Carcinogenesis 1994 15 : 2201 6.
22. Kawaguchi K, Sakaida I, Tsuchiya M et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficientL-amino acid-defined diet. Biochem. Biophys. Res. Commun. 2004 315 : 187 95.
23. Denda A, Endoh T, Tang Q et al. Prevention by inhibitors of arachidonic acid cascade of liver carcinogensis, cirrhosis and oxidative DNA damage caused by acholine-deficient,1-amino acid defined diet in rats. Mutat. Res. 1998 402 : 279 88.
24. Sakaida I, Okita K. The role of oxidative stress in NASH and fatty liver model. Hepatol. Res. 2005 33 : 128 31.
25. Sakaida I, Tsuchiya M, Kawaguchi K et al. Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient 1-amino acid defined diet. J. Hepatol. 2003 38 : 762 9.
26. Hashimoto E, Yatsuji S, Kaneda H et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol. Res. 2005 33 : 72 6.
27. Riera M, Chillon M, Aran J et al. Intramuscular SP 1017-formuklated DNA electrotransfer enhances transgene expression and distributes hHGF to different rat tissues. J. Gene Med. 2004 6 : 111 18.
28. Marshall E. Gene therapy death prompts review of adenovirus vector. Sicence 1999 286 : 2244 5.
29. Hickman M, Malone R, Lehmann-Bruinsma K et al. Gene expression following direct injection of DNA into liver. Hum. Gene Ther. 1994 5 : 1477 83.
30. Tahara M, Matsumoto K, Nukiwa T et al. Hepatocyte growth factor leads to recovery from alchol-induced fatty liver in rats. J. Clin. Invest. 1999 103 : 313 20.
31. Ramirez R, Hus D, Patel A et al. Over-expression of hepatocyte growth factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with thyroid carcinoma. Clin. Endocrinol. 2000 53 : 635 44.
32. Hide Y, Morita T, Fujita M et al. Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers. Oncol. Rep. 1999 6 : 1051 6.
33. Wu CW, Li AF, Chi CW et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol. Rep. 1998 5 : 817 22.
34. Ueki T, Fujimoto J, Suzuki T et al. Expression of hepatocyte growth factor and its receptor c-met protooncogene in hepatocellular carcinoma. Hepatology 1997 25 : 862 6.
35. Takanami I, Tanaka F, Hashizume T et al. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 1996 53 : 392 7.
36. Baykal C, Ayhan A, Ai A et al. Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol. Oncol. 2003 88 : 123 9.
37. Oda Y, Sakamoto A, Saito T et al. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-Met correlates with poor prognosis in synovial sarcoma. Hum. Pathol. 2000 31 : 185 92.